Cocrystal Pharma, Inc. reported financial results for the year ended December 31, 2025.
“Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the year ended December 31, 2025”
Cocrystal Pharma, Inc. — fact timeline
Source-grounded facts extracted from Cocrystal Pharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cocrystal Pharma, Inc.: Amended the quorum requirement to one third of the voting power of outstanding shares of all classes or series of voting stock (effective 2025-06-17).
“On June 17, 2025, the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws to the quorum requirement to provide that one third of the aggregate voting power of the outstanding shares of all classes or series of voting stock then entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of stockholders (the “Amendment”).”
Cocrystal Pharma, Inc. reported financial results for Q1 2024.
“Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.”
Cocrystal Pharma, Inc. reported financial results for the 12 months ended December 31, 2023.
“Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.